b Gallium (Ga) is an iron mimetic that has successfully been repurposed for antibacterial chemotherapy. To improve the antibacterial potency of Ga on Pseudomonas aeruginosa, the effect of complexation with a variety of siderophores and synthetic chelators was tested. Ga complexed with the pyochelin siderophore (at a 1:2 ratio) was more efficient than Ga(NO 3 ) 3 in inhibiting P. aeruginosa growth, and its activity was dependent on increased Ga entrance into the cell through the pyochelin translocon.
I
ron (Fe) is an essential nutrient for nearly all forms of life, being the cofactor of many vital enzymes involved in DNA synthesis, metabolism, and the oxidative stress response (1) . Pathogenic bacteria must counteract an Fe-poor environment during infection, since Fe is unavailable to invading pathogens due to sequestration by the Fe carrier and storage proteins of the host (2) . Bacteria have evolved multiple strategies to acquire Fe from the host, the most common being through the production of siderophores. These compounds are secreted in the extracellular milieu, where they form stable complexes with Fe and other transition metals (depending on their coordination chemistry) and convey the metal to the bacterial cell via specific active transport systems (3) . Given the importance of Fe in bacterial metabolism and the paucity of effective antibiotics for multidrug-resistant bacteria, Fe uptake and metabolism have recently been assessed as targets for the development of new antibacterials (4-7).
Gallium (Ga III ) is a semimetal that shares a number of chemical similarities with the oxidized Fe form (Fe III (8) . The antimicrobial properties of Ga(NO 3 ) 3 , the active component of the FDA-approved formulation Ganite (Genta), have been investigated in a number of species (recently reviewed in references 9-12). In particular, Ga III inhibits both planktonic and biofilm growth of the opportunistic pathogen Pseudomonas aeruginosa and causes significant protection from P. aeruginosa infection in animal models (13, 14) .
In the present study, we attempted to improve the antibacterial activity of Ga III on P. aeruginosa by complexation with suitable carriers (either synthetic chelators or siderophores) that are actively taken up by the bacterium and that stimulate, to a variable extent, its growth under conditions of extreme Fe deficiency (see Fig. S1 in the supplemental material). Both the P. aeruginosa reference strain PAO1 and the cystic fibrosis isolate TR1 (15) were used for growth promotion/inhibition assays. Ga III -chelator complexes were generated by mixing, in the appropriate ratios (Fig. 1) , aqueous solutions of Ga(NO 3 ) 3 with ferrichrome (FER) (Sigma), sodium dicitrate (CIT) (Sigma), desferrioxamine (DFO) (Novartis), sodium salicylate (SAL) (Sigma), and the autologous siderophores pyoverdine (PVD) and pyochelin (PCH). PVD and PCH were purified from culture supernatants of a PCH-defective P. aeruginosa mutant (PAO1⌬pchD; see Table S1 and Supplemental Experimental Procedures in the supplemental material) and a PVD-defective P. aeruginosa mutant (PAO1⌬pvdA) (16), respectively, according to previously published procedures (17) (18) (19) . The growth inhibitory activity of each Ga III complex was then assayed in the Fe-poor medium DCAA (18) and compared to the activity of each chelator or Ga(NO 3 ) 3 alone ( (13), Ga(NO 3 ) 3 inhibited P. aeruginosa growth in a dose-dependent manner at concentrations of Ͼ3.13 M. Consistent with previous findings (13), Ga(NO 3 ) 3 showed bacteriostatic activity at a growth inhibitory concentration (12.5 M; data not shown).
The PCH-Ga III complex was the only combination endowed with higher inhibitory activity than that of Ga(NO 3 ) 3 alone. PVDGa III , SAL-Ga III , and CIT-Ga III complexes showed a moderate protective effect on P. aeruginosa, since they decreased Ga III -mediated growth inhibition in a dose-dependent manner. Notably, FER-Ga III and DFO-Ga III abrogated growth inhibition by Ga III , as one would expect for a compound endowed with strong Ga IIIscavenging activity ( It appears, therefore, that some Ga III complexes alleviate Ga III inhibition rather than potentiate it, suggesting that they behave as Ga III scavengers rather than vehicles of Ga III to the cell. To gain further insight into the effect of the different chelators on Ga III activity, bacteria were grown in DCAA containing Ga(NO 3 ) 3 at a fixed inhibitory concentration (12.5 M) and increasing concentrations of the different chelators in order to obtain different chelator-to-Ga III ratios (Fig. 2) . DFO and FER protected P. aeruginosa from the growth inhibitory activity of Ga(NO 3 ) 3 , even at 1:2 and 1:4 chelator-to-Ga III ratios, which is suggestive of a strong Ga III scavenging effect (Fig. 2) . Similar results were obtained with PVD, though at higher PVD-to-Ga III ratios. SAL and CIT showed a poor scavenging effect, being unable to counteract the Ga(NO 3 ) 3 inhibitory effect even in the presence of an excess of chelator (chelatorto-Ga III ratio, 4:1). PCH never rescued P. aeruginosa growth in the presence of Ga(NO 3 ) 3 at all ratios tested (Fig. 2) . Again, comparable results were obtained for the P. aeruginosa clinical strain TR1 (see Fig. S3 in the supplemental material). Taken together, these results indicate that DFO, FER, and PVD are strong inhibitors of Ga III activity, while PCH exerts an opposite effect, suggesting that PCH acts as a "Trojan horse" that conveys Ga III into the cell. To shed more light on the mechanism by which PCH potentiates Ga III activity, we generated P. aeruginosa PAO1 mutants impaired in PCH biosynthesis (⌬pchD) or uptake (⌬fptAX and ⌬fptX, with deletions of the whole PCH translocon or the inner membrane transporter only, respectively) (for details, see reference 20; see also Table S1 and Supplemental Experimental Procedures in the supplemental material). We reasoned that if the Ga III inhibitory effects were enhanced by PCH production and internalization, these PCH synthesis and uptake mutants would be more resistant to Ga(NO 3 ) 3 . The effect of Ga(NO 3 ) 3 on these strains was thus assessed in DCAA supplemented with increasing Ga(NO 3 ) 3 concentrations (0 to 100 M), and the data were expressed as the MICs at 24 h and 48 h (Fig. 3A) . While all strains showed comparable growth levels in DCAA without Ga(NO 3 ) 3 (data not shown), the ⌬pchD, ⌬fptAX, and ⌬fptX strains were more resistant to Ga(NO 3 ) 3 than the wild-type PAO1 (Fig. 3A) , suggesting that PCH production and transport into the cell contribute to Ga III inhibitory activity. To confirm that the reduction of Ga III susceptibility in PCH-defective mutants was due to impaired internalization of Ga III into the cell, intracellular Ga III levels were measured in each strain grown in DCAA supplemented with a subinhibitory Ga(NO 3 ) 3 concentration (3 M) by means of inductively coupled plasma optical emission spectrometry (ICP-OES) using an ICP-OES Varian 710 spectrometer (Agilent Technologies) (Fig. 3B) . In line with the higher resistance shown by the ⌬pchD, ⌬fptAX, and ⌬fptX mutants, the intracellular levels of Ga III were significantly lower in these mutants than those in wildtype PAO1 (Fig. 3B) , although not nil, suggesting that Ga III may enter the cell via an alternative route(s). This is consistent with the recent finding that the HitAB Fe transport system is also involved in Ga III uptake by P. aeruginosa (21) . In conclusion, our data demonstrate that siderophores and synthetic chelators affect in different manners the in vitro activity of Ga III on P. aeruginosa. Among many Ga III complexes tested, only the endogenous siderophore PCH facilitates Ga III entrance into the cell through its specific uptake machinery, thereby potentiating the antipseudomonal activity of Ga III . These findings might be of guidance for the future design of more effective Ga III delivery systems to P. aeruginosa. 
FIG 2 Effect of different chelator-to-Ga
III ratios on P. aeruginosa PAO1 growth. P. aeruginosa PAO1 was grown for 24 h at 37°C in microtiter plates containing (per well) 200 l DCAA supplemented with 12.5 M Ga(NO 3 ) 3 and various concentrations of each chelator to obtain different chelator-to-Ga III ratios. The chelator-to-Ga III ratio (x axis) takes into account the binding stoichiometry, as indicated in the inset of each panel. The actual chelator-to-Ga III ratio is given in parentheses on the x axis. CTL ϩ , growth in the presence of 12.5 M Ga(NO 3 ) 3 ; CTL Ϫ , growth without chelators or Ga(NO 3 ) 3 . Growth was measured as the OD 600 (y axis). Each value is the mean Ϯ standard deviation from the results of three independent experiments. Statistically significant differences compared to CTL ϩ are indicated (analysis of variance [ANOVA]): *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001.
FIG 3 Ga
III inhibitory activity and intracellular Ga III levels in P. aeruginosa PAO1 and isogenic PCH-defective mutants. (A) MICs of Ga(NO 3 ) 3 (M) for P. aeruginosa PAO1 and isogenic PCH-transport mutants grown for 24 h and 48 h in 200 l DCAA supplemented with increasing Ga(NO 3 ) 3 concentrations (0 to 100 M). (B) Intracellular concentrations of Ga III in the same P. aeruginosa strains grown in DCAA supplemented with 3 M Ga(NO 3 ) 3 for 14 h, measured by the means of ICP-OES. The values are expressed as the percentage relative to PAO1 and represent the mean Ϯ standard deviation from three independent experiments. Intracellular Ga III levels in wild-type PAO1 varied from 0.47 to 1.41 ng Ga III /mg total cell proteins, depending on the experiment. *, statistically significant differences relative to PAO1 (P Ͻ 0.05, ANOVA).
